Patient advocacy groups play an integral role in supporting those impacted by uncommon and underserved medical conditions. With a focus on access to resources and care, the work of non-profit organizations around the world is critical in helping address the unmet needs facing patients and their families. Since 2011, Sanofi Genzyme has provided the Patient Advocacy Leadership (PAL) Award Grant, which has helped these organizations fulfill their missions by funding unique projects for patients living with lysosomal storage disorders (LSDs), a group of rare diseases that can cause debilitating health problems.
This year, five recipients were chosen from a diverse group of 32 global candidates who submitted compelling proposals supporting the LSD patient community. After careful consideration, an independent external review committee selected the winning recipients from Romania, Australia/New Zealand, France, Italy and India.
“Each year, the recipients of the PAL Award Grant support different needs facing the lysosomal storage disorder patient community,” said Sebastien Martel, Global Head of Rare Diseases. “Their work is critical to raising awareness, optimizing care and meeting the ever-growing needs of those living with rare diseases across globe.”
“Since the program’s inception, Sanofi Genzyme has awarded more than $900,000 to support 57 projects, including patient workshops, advocacy trainings, awareness campaigns and research, proposed by organizations across 28 countries.
We are proud to announce the 2019 PAL Award recipients: